Press Release

Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, PA / OCTOBER 21, 2026 / Geneos Therapeutics, a clinical stage biotherapeutics … Read more

Participants in early clinical trial had increased immune response, slowed tumor progression by Mark Reynolds May 12, 2026                                                                                 … Read more

Trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate

Philadelphia, PA – March 6, 2024 – Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, … Read more

Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer

By RECIST1.1, Three Complete Responses and Seven Durable Partial Responses Achieved to Date–

Nomination Recognizes Progress and Promise of Geneos’ Personalized Therapeutic Cancer Vaccines

Proceeds to Fund Expansion of Phase 1b/2a Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer

To Date, Four Patients Are Now Cancer Free Out of 23 Evaluable

Overall Response Rate 30.4 Percent in 23 Evaluable Patients Including Two Complete Responses and a Third Cancer-Free Patient